ONCT Oncternal Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ONCT

Price (delayed)

$6.73

Market cap

$19.92M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$12.26

Enterprise value

$13.8M

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on ...

Highlights
The gross profit has grown by 47% from the previous quarter and by 22% YoY
ONCT's revenue is up by 47% since the previous quarter and by 22% year-on-year
ONCT's equity has plunged by 56% YoY and by 24% from the previous quarter
The quick ratio has plunged by 55% YoY and by 33% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.oncternal.com
Peers: OMGA

Key stats

What are the main financial stats of ONCT
Market
Shares outstanding
2.96M
Market cap
$19.92M
Enterprise value
$13.8M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.87
Price to sales (P/S)
17.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.99
Earnings
Revenue
$1.15M
EBIT
-$36.38M
EBITDA
-$36.21M
Free cash flow
-$28.63M
Per share
EPS
-$12.26
Free cash flow per share
-$9.68
Book value per share
$7.75
Revenue per share
$0.39
TBVPS
$9.85
Balance sheet
Total assets
$29.14M
Total liabilities
$6.22M
Debt
$278,000
Equity
$22.93M
Working capital
$22.39M
Liquidity
Debt to equity
0.01
Current ratio
4.66
Quick ratio
4.42
Net debt/EBITDA
0.17
Margins
EBITDA margin
-3,146%
Gross margin
100%
Net margin
-3,160.7%
Operating margin
-3,331.9%
Efficiency
Return on assets
-91%
Return on equity
-107.7%
Return on invested capital
-151.6%
Return on capital employed
-158%
Return on sales
-3,160.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ONCT stock price

How has the Oncternal Therapeutics stock price performed over time
Intraday
-2.32%
1 week
-4.94%
1 month
-14.38%
1 year
-16.93%
YTD
-37.24%
QTD
-11.45%

Financial performance

How have Oncternal Therapeutics's revenue and profit performed over time
Revenue
$1.15M
Gross profit
$1.15M
Operating income
-$38.35M
Net income
-$36.38M
Gross margin
100%
Net margin
-3,160.7%
The gross profit has grown by 47% from the previous quarter and by 22% YoY
ONCT's revenue is up by 47% since the previous quarter and by 22% year-on-year
The operating margin has increased by 37% since the previous quarter and by 33% year-on-year
Oncternal Therapeutics's net margin has increased by 37% from the previous quarter and by 35% YoY

Growth

What is Oncternal Therapeutics's growth rate over time

Valuation

What is Oncternal Therapeutics stock price valuation
P/E
N/A
P/B
0.87
P/S
17.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.99
The EPS is up by 27% year-on-year and by 9% since the previous quarter
ONCT's price to book (P/B) is 57% less than its 5-year quarterly average of 2.0 but 8% more than its last 4 quarters average of 0.8
ONCT's equity has plunged by 56% YoY and by 24% from the previous quarter
ONCT's price to sales (P/S) is 48% lower than its 5-year quarterly average of 33.0 and 40% lower than its last 4 quarters average of 28.4
ONCT's revenue is up by 47% since the previous quarter and by 22% year-on-year

Efficiency

How efficient is Oncternal Therapeutics business performance
ONCT's return on equity has dropped by 51% year-on-year and by 12% since the previous quarter
The return on invested capital has surged by 51% year-on-year but it has declined by 16% since the previous quarter
The return on assets has declined by 42% year-on-year and by 9% since the previous quarter
The return on sales is up by 37% since the previous quarter and by 35% year-on-year

Dividends

What is ONCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ONCT.

Financial health

How did Oncternal Therapeutics financials performed over time
The current ratio has plunged by 56% YoY and by 33% from the previous quarter
The quick ratio has plunged by 55% YoY and by 33% from the previous quarter
Oncternal Therapeutics's debt is 99% less than its equity
ONCT's equity has plunged by 56% YoY and by 24% from the previous quarter
Oncternal Therapeutics's debt has decreased by 13% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.